News from hansa biopharma ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 18, 2019, 02:13 ET Hansa Biopharma Interim Report January-June 2019

Imlifidase benefits highlighted in recent ATC presentations. Expansion outside transplantation with initiation of study in Guillain-Barré Syndrome...


Jul 05, 2019, 06:11 ET Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update

On 18 July 2019, at 08:00 CET, Hansa Biopharma will publish its Business Update for the second quarter of 2019. All interested parties are invited to ...


Jun 07, 2019, 02:15 ET Plenary Presentation at the 2019 American Transplant Congress Demonstrates Significant Reduction in Time on the Waitlist for Patients Treated with Imlifidase Compared to Matched Controls

Hansa Biopharma AB ("Hansa") (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced...


May 13, 2019, 02:11 ET Hansa Biopharma to Participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that...


May 02, 2019, 02:19 ET Hansa Biopharma Announces Upcoming Presentations at the 2019 American Transplant Congress

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that...


Apr 29, 2019, 02:19 ET Hansa Biopharma Interim Report January-March 2019

January – March 2019 Highlights The European Medicines Agency (EMA) accepted Hansa's Marketing Authorization Application (MAA) for review of IDEFIRIX ...


Apr 17, 2019, 02:26 ET Notice to Annual General Meeting in Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), Reg. No. 556734-5359, with registered office in Lund, summons to Annual General Meeting on Wednesday 22 Maj 2019 at 17.00...


Apr 15, 2019, 02:54 ET Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it ...


Apr 15, 2019, 02:23 ET Hansa Biopharma Divests its Equity Holding in Genovis

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it ...


Apr 15, 2019, 02:12 ET Hansa Biopharma Publishes the Annual Report for 2018

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that...


Mar 26, 2019, 03:19 ET Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it ...


Mar 21, 2019, 03:19 ET Hansa Biopharma Announces Selection of NiceR Lead Candidate

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that...


Mar 06, 2019, 02:26 ET Hansa Biopharma to Present at the Cowen 39th Annual Health Care Conference

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that...


Mar 01, 2019, 02:28 ET Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX™ (imlifidase)

Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that...


Feb 07, 2019, 02:37 ET Hansa Biopharma Appoints Donato Spota as New Chief Financial Officer

Hansa Biopharma AB, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, today announced the appointment of Mr. Donato...